Introduction
Heart failure (HF) is a worldwide public health problem in developed countries, approximately 2% of the adult population has HF, a prevalence that increases exponentially with age, as it is less than 1% before the 50 years and then doubles with each decade to exceed 8% among those over 75 years [1, 2] .
HF is the inability of the heart to pump blood properly according to the needs of the hepatic metabolism; if it succeeds, it does so at the expense of an abnormal elevation of the filling pressure of the cardiac ventricles either by myocardial disease or excessive overload. This brings with it a neurohormonal response with effort intolerance, fluid retention and reduced longevity.
In 2003, the American Heart Association (AHA) reported that 48 million hospital discharges occurred in the United States with this diagnosis [3] . In the Framingham study, HF in men aged 50-59 years was 8 per 1,000 inhabitants and increasing to 70 per 1,000 in patients over 80 years (very similar numbers in women) [4] .
However, in Africa it has a rather different etiology to that described in Europe and America, it is related to the degree of development of the continent and affects predominantly a young population. Damasceno, in his study on heart failure in Africa, throughout a meta-analysis including studies published up to 2007 by Bongani Mayosi et al. [5] found that arterial hypertension was the main cause of heart failure followed by cardiomyopathies.
The current therapeutic approach of patients with HF is aimed at improving signs and symptoms, correcting volume overload, increasing end-organ perfusion, improving cardiac contractility and hemodynamic status [6] .
During the last 24 years, the mechanisms of action of ozone in human blood have been clarified [7] . It is stated that its therapeutic properties are: improving the metabolism of oxygen, modulate biological oxidative stress, modulate the immune system, intervene in the synthesis and / or release of autacoids (endogenous substances with diverse actions physiological and pharmacological), regulate metabolism, in addition to exert a great effect as germicide [8] .
For all of the above, our team decided to analyze the clinical and echocardiographic (LVEF) effects induced by major autohemotherapy applied in patients with CHF.
Materials and methods
A retrospective cross-sectional study was performed at the Cardiozono Medical Center located in Luanda, Angola. The final sample consisted of 45 patients of both sexes, who presented a diagnosis of CHF, referred from our Cardiology Department and other Hospital offices, who started treatment of ozone therapy indistinctly in the period from June 2014 to June 2017. We emphasize that in our work we performed an analysis of the patients treated in this time period of their evolution corresponding to one year performing the therapy.
Inclusion criteria were:
Patients with a diagnosis of HFC class II-III of the New York Heart Association (NYHA) [9] and American Cardiology College / American Heart Association (ACC / AHA), previous echocardiography with a (LVEF) between 35% and 50% and patients with a time greater than 6 months of treatment with furosemide 40 mg at 8 hours and 40 mg at 16 hours, spironolactone 50 mg every 12 hours, hydrochlorothiazide 25 mg daily, carvedilol 12.5 mg every 12 hours, mononitrate of isosorbide 20 mg daily and aspirin 100 mg daily. During the period of time analyzed. 45 patients were included in the treatment, 20 were women and 25 men, the age of the patients was from 40 to 65 years, (60 to 65 years, 20 patients, 11 women and 9 men, from 50 to 59 years, 20 patients, 13 men and 7 women and from 40 to 49 years old, 5 patients, 3 men and 2 women).
Exclusion criteria were:
Patients with HF of a diagnosis (less than 6 months) with medical treatment and patients with secondary HF produced by autoimmune diseases.
Treatment Protocol:
The patients received 15 sessions of major autohemotherapy (one daily session). In each session we used a German-made Promedic Humazon equipment (Humares GmbH, Bruchsal, Germany), 3-way stopcock, epicranial needle 19 G, Sangiset (Humares GmbH, Bruchsal, Germany) with capacity of 350 mL where we put 10 mL of 3.13 % sodium citrate to avoid blood clot during the procedure and other disposable material.
The major autohemotherapy ( Table 1 ) was performed at a concentration of 50 μg / mL in 100 m of blood; the initial dose of the therapy was 4000 μg (80 mL of ozone gas at 50 μg / mL concentration); we increased the dose by 2000 μg every 2 days until reaching a dose of 12000 μg (240 mL of ozone gas at 50 μg / mL concentration), maintaining this dose as a maintenance dose every 15 days throughout the year.
The parameters evaluated were:
• Heart failure Functional Classification according NYHA [9] (New York Heart Association) ( improves the metabolism of the cardiac muscle, increases the circulating serotonin and causes a cardioprotective effect already mentioned in previous studies [11, 12] .
Conclusions
This study strongly suggests that the application of major autohemoterapy produced a clinical and functional improvement in patients with CHF, evidencing its effectiveness as adjuvant therapy. 
